-
Ultimovacs ASA – Announces Positive 5-Year Overall Survival Update from Phase I Combination Trial Evaluating Universal Cancer Vaccine UV1 in Metastatic Melanoma
-
Ultimovacs ASA – Announces the Appointment of Ton Berkien as Chief Business Officer
-
Ultimovacs ASA: Third quarter 2020 result presentation
-
Ultimovacs ASA – Extraordinary General Meeting held on 11 November 2020
-
Ultimovacs ASA: Invitation to third quarter 2020 results webcast presentation
-
Ultimovacs ASA – Disclosure of voting rights of Extraordinary General Meeting
-
Ultimovacs announces Acceptance of Publication in ‘Frontiers in Immunology’ featuring positive results from Phase I trial evaluating UV1 in Non-Small Cell Lung Cancer
-
Ultimovacs ASA: Notice of Extraordinary General Meeting on 11 November 2020 – proposed changes to the Board of Directors
-
Ultimovacs Announces Updated Positive Results from Phase I Trial Evaluating Universal Cancer Vaccine, UV1, in Non-Small Cell Lung Cancer
-
Ultimovacs Announces Positive Topline Results from Phase I Combination Trial Evaluating Universal Cancer Vaccine, UV1, in Malignant Melanoma Patients
